Taipei, Taiwan, Nov. 24, 2025 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced that the Company has reached a set of regulatory and clinical milestones that together mark its first commercial entry into U.S. eye care and limbal stem cells (“LSC”) exosome‑based therapeutics. Through its partner 3D Global Biotech Inc. (“3D Global Biotech”), Exovisse ...

Core Viewpoint - A class action lawsuit has been filed against MoonLake Immunotherapeutics for allegedly misleading investors regarding the efficacy of its drug candidate, sonelokimab (SLK), which reportedly failed to meet clinical benchmarks [1][3][4]. Company Overview - MoonLake Immunotherapeutics is a clinical-stage biotech firm based in Zug, Switzerland, focusing on next-generation immunotherapies [2]. Legal Proceedings - The lawsuit is on behalf of investors who purchased MoonLake shares between March 10, 2024, and September 29, 2025, with a deadline of December 15, 2025, for investors to seek lead plaintiff status [1][2]. Drug Candidate Details - MoonLake promoted SLK as a breakthrough treatment due to its Nanobody structure but allegedly failed to disclose that it targets the same molecules as BIMZELX, an FDA-approved monoclonal antibody, indicating it was not clinically superior [3]. Trial Results and Market Impact - On September 28, 2025, MoonLake disclosed that SLK did not meet efficacy benchmarks in Phase 3 trials, leading to a significant stock price decline of $55.75 per share, nearly 90%, in one trading session [4].

Core Viewpoint - ProMIS Neurosciences Inc. has announced a one-for-twenty-five reverse stock split to comply with Nasdaq listing requirements and aims to increase the market price of its common shares [1][11]. Group 1: Reverse Stock Split Details - The reverse stock split will take effect at 12:01 a.m. Eastern Time on November 28, 2025, with shares trading on a split-adjusted basis from that date [2]. - The number of outstanding common shares will decrease from approximately 53,811,110 shares to about 2,152,444 shares [3]. - Proportional adjustments will be made to equity incentive plans, stock options, and outstanding warrants in accordance with the reverse stock split [4]. Group 2: Compliance with Nasdaq - ProMIS received a deficiency letter from Nasdaq on January 8, 2025, indicating that its common shares had not maintained the minimum required closing bid price of at least $1.00 [8]. - The company was granted an additional 180-day compliance period until December 29, 2025, to regain compliance with the Bid Price Rule [10]. - The reverse stock split is part of the company's strategy to cure the deficiency and meet Nasdaq's listing standards [11]. Group 3: Shareholder Information - No fractional shares will be issued; shareholders entitled to fractional shares will receive cash instead [5]. - Stockholders with shares held in book-entry form or through a bank or broker will see the effects of the reverse stock split reflected in their accounts without needing to take action [6]. Group 4: Company Overview - ProMIS Neurosciences is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative disorders, including Alzheimer's disease [13]. - The company utilizes its proprietary target discovery engine, EpiSelect™, to identify novel targets associated with misfolded proteins [13].

Core Insights - Adaptive Biotechnologies Corporation's clonoSEQ test is gaining recognition as a standard-of-care tool for personalizing patient care and accelerating drug development, with a record-setting presence at the upcoming ASH meeting [1][2] - The inclusion of clonoSEQ in 89 abstracts, including 36 oral presentations, at the 67th Annual Meeting of the American Society of Hematology (ASH) highlights its integral role in modern lymphoid cancer care [1][2] Company Overview - Adaptive Biotechnologies is a commercial-stage biotechnology company focused on translating the genetics of the adaptive immune system into clinical products for disease diagnosis and treatment [6] - The company aims to develop immune-driven clinical products tailored to individual patients, leveraging its proprietary immune medicine platform [6][8] Product Details - clonoSEQ is the first and only FDA-cleared in vitro diagnostic test for detecting and tracking minimal residual disease (MRD) in multiple myeloma, B-cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia, among others [3][4] - The test can identify and quantify DNA sequences in malignant cells, detecting one cancer cell in one million healthy cells, which aids in assessing and monitoring MRD with precision [4] Clinical Impact - The abstracts featuring clonoSEQ data cover various blood cancers, underscoring its position as the most widely used and validated next-generation sequencing-based MRD test in lymphoid malignancies [7] - More than 17 presentations will demonstrate how clonoSEQ MRD assessment informs treatment decisions in real-world clinical practice across multiple cancer types [7]

Core Points - Vaxil Bio Ltd. announced a non-brokered private placement offering of up to 3,111,111 units at a price of $0.1125 per unit, aiming to raise gross proceeds of up to $350,000 [2][3] - Each unit consists of one common share and one share purchase warrant, with warrants allowing the purchase of additional shares at $0.15 for five years [2] - The net proceeds will be used for general corporate purposes, and the offering is expected to close around December 4, 2025, pending approval from the TSX Venture Exchange [3] Financial Details - The company will pay finders a cash commission of up to 8% of the gross proceeds and issue non-transferrable warrants equal to 8% of the total units issued [4] - The units, shares, and warrants will be subject to a hold period of four months and one day from the date of issue [4] Company Background - Vaxil is an immunotherapy biotech company focused on targeting cancer markers and infectious diseases, with its lead product being ImMucin™, which has received orphan drug status from the FDA and EMA [5] - The company is exploring other business opportunities to enhance shareholder value, which may or may not be within the biotechnology sector [5]

NEW YORK and WALTHAM, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced the Company’s participation in the 8th Annual Evercore Healthcare Conference in Coral Gables, Florida. Marino Garcia, CEO of Dianthus Therapeutics, will participate in a fireside chat on Tuesday, December 2, 2025 at 2:35 p.m. ET and will host ...

Core Viewpoint - MoonLake Immunotherapeutics (MLTX) is facing securities fraud allegations after a significant stock price drop of nearly 90%, prompting investors to seek legal recourse [1][3]. Group 1: Company Overview - MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases [4]. - The company was conducting Phase 3 VELA trials for sonelokimab (SLK), aimed at treating moderate to severe hidradenitis suppurativa (HS) [4]. Group 2: Allegations and Legal Action - A lawsuit has been filed against MoonLake and its senior executives for potential violations of federal securities laws, specifically under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [3]. - The complaint claims that MoonLake misrepresented its clinical data and the advantages of its Nanobody structure over competitors, which undermined the drug's regulatory approval and commercial viability [6]. Group 3: Stock Performance and Impact - Following the announcement of disappointing results from the VELA Phase 3 trials on September 28, 2025, MoonLake's stock plummeted from $61.99 per share to $6.24 per share, a decline of $55.75 or nearly 90% [7].

Group 1 - The biotech industry is characterized by lengthy processes where companies incur significant costs while awaiting results from drug candidates, which often leads to binary outcomes [1] - There is a strong inclination towards investing in high-growth companies within sectors that are expected to experience exponential growth [1] - The focus is on understanding and investing in disruptive technologies and innovative enterprises, combining fundamental analysis with future trend predictions [1] Group 2 - The belief in the potential of innovation to generate substantial returns is emphasized, with a commitment to providing insightful analysis on relevant companies [1]

Biotech and healthcare stocks saw notable activity in Friday's after-hours trading session, with several names posting sharp moves on the back of corporate updates and investor anticipation. Here are the highlights from November 21, 2025.Butterfly Network, Inc. (BFLY) shares climbed in extended trading, rising 6.04% to $2.81 after adding $0.16. At the close, the stock had already surged 14.22% to $2.65. The digital company announced that CEO Joseph DeVivo and Interim CFO Megan Carlson will participate in a ...

Core Insights - Cerus Corporation (CERS) is a biotechnology company focused on developing transfusion-safety solutions to ensure a reliable and pathogen-reduced blood supply [1] Group 1: Company Overview - Cerus Corporation produces the Intercept Blood System, which includes devices, disposables, and consumables for platelets and plasma [1]